Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BOSTON and COPENHAGEN, Denmark, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer,...
-
GB1211, a potent oral small molecule galectin-3 inhibitor was well tolerated in Phase 1 studiesPhase 2a study planned to establish the anti-fibrotic effects of GB1211 in grade 2 to 4 Non-Alcoholic...
-
The EMA cited GB0139’s clinically relevant biomarker data in IPF patientsSignificant reduction of YKL-40 biomarker in fibrosis, inflammation, tissue remodeling diseases BOSTON and COPENHAGEN,...
-
Appoints Amit Munshi as Chair, deeply experienced industry executive, CEO of Arena PharmaceuticalsSucceeds Magnus Persson, who oversaw period of rapid growth and success for GalectoAppoints David...
-
Recruitment on track in international “GALACTIC-1” Phase 2b IPF studyOver 150 patients recruited to date with data readout expected in 2022Galecto continues to build strong portfolio in fibrosis and...
-
GB0139 showed pharmacodynamic evidence with reduction of galectin-3Direct link to clinical results in IPF patients after 14 days treatmentLead compound being developed in Phase 2b trial, with readout...
-
COPENHAGEN, Denmark, April 27, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
-
Dr. Lindmark brings broad R&D expertise, particularly in respiratory and inflammationAppointment reinforces Galecto’s ambition to be a global player following PharmAkea merger COPENHAGEN,...
-
Clinical programs in IPF, NASH and cancerJoint entity to be named Galecto, Inc. SAN DIEGO and COPENHAGEN, Denmark, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Galecto, the leading developer of galectin...